Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04698824
Other study ID # 2020-A03469-30
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 2021
Est. completion date October 2021

Study information

Verified date May 2021
Source University Hospital, Grenoble
Contact Maxime LUGOSI, PhD
Phone 04 76 76 37 07
Email mlugosi@chu-grenoble.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Description of the short and long-term impact of hypnosis sessions for patient having benefited from at least one hypnosis session in internal medicine at the french hospital "Groupe Hospitalier Mutualiste de Grenoble", with the help of a qualitative survey made by phone.


Description:

The practice of hypnosis has experienced a recent boom in medicine, with a multiplication of its fields of action. Regarding internal medicine, the influence of the psyche on the immune system makes the use of hypnosis particularly relevant for autoimmune diseases. Medically unexplained symptoms (another important field of internal medicine) are also strongly psychosomatic and thus susceptible to hypnosis. The hypothesis is thus made that hypnosis can bring multiple benefits to internal medicine patients. The main objective of this study is to describe the short and long-term impact of hypnosis sessions for patient having benefited from at least one hypnosis session in internal medicine at the french hospital "Groupe Hospitalier Mutualiste de Grenoble", with the help of a qualitative survey made by phone. Moreover retrospective medical data concerning these patients will be collected to determine their medical history, their main symptoms et reasons to use hypnosis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 70
Est. completion date October 2021
Est. primary completion date July 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All consecutive patients who had at least one hypnosis session in internal medicine at the hospital "Groupe Hospitalier Mutualiste de Grenoble" between 08/28/2015 (date of the very first hypnosis consultation in internal medicine) and 03/17/2020 (date of confinement due to Covid19 in France) Exclusion Criteria: - Patient who had a hypnosis session, but who is not followed for a pathology in internal medicine or in internal medicine with a pneumological orientation

Study Design


Intervention

Procedure:
Hypnosis session
At least one session of hypnosis in the internal medicine unit at the hospital "Groupe Hospitalier Mutualiste de Grenoble"

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Grenoble Groupe Hospitalier Mutualiste de Grenoble

References & Publications (4)

Günther SC, Schwebel C, Hamidfar-Roy R, Bonadona A, Lugosi M, Ara-Somohano C, Minet C, Potton L, Cartier JC, Vésin A, Chautemps M, Styfalova L, Ruckly S, Timsit JF. Complications of intravascular catheters in ICU: definitions, incidence and severity. A randomized controlled trial comparing usual transparent dressings versus new-generation dressings (the ADVANCED study). Intensive Care Med. 2016 Nov;42(11):1753-1765. Epub 2016 Oct 12. — View Citation

Lugosi M, Alberti C, Zahar JR, Garrouste M, Lemiale V, Descorps-Desclère A, Ricard JD, Goldgran-Tolédano D, Cohen Y, Schwebel C, Vésin A, Timsit JF, Azoulay E. Aspergillus in the lower respiratory tract of immunocompetent critically ill patients. J Infect. 2014 Sep;69(3):284-92. doi: 10.1016/j.jinf.2014.04.010. Epub 2014 Jun 9. — View Citation

Lugosi M, Sacré K, Lidove O, Chauveheid MP, Brihaye B, Laissy JP, Chauchard M, Papo T. [Long-term follow-up of a French cohort of retroperitoneal fibrosis]. Rev Med Interne. 2013 Oct;34(10):591-9. doi: 10.1016/j.revmed.2013.02.002. Epub 2013 Mar 14. French. — View Citation

Tolsma V, Schwebel C, Azoulay E, Darmon M, Souweine B, Vesin A, Goldgran-Toledano D, Lugosi M, Jamali S, Cheval C, Adrie C, Kallel H, Descorps-Declere A, Garrouste-Orgeas M, Bouadma L, Timsit JF. Sepsis severe or septic shock: outcome according to immune status and immunodeficiency profile. Chest. 2014 Nov;146(5):1205-1213. doi: 10.1378/chest.13-2618. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Description of the short and long-term impact of hypnosis sessions thanks to a qualitative phone survey Improvement in symptoms and quality of life, assessed thanks to a qualitative phone survey by 5-levels Likert scales Assessed only once. Phone call will be performed between march 2021 and June 2021
Secondary Assessment of the reasons for patient satisfaction / dissatisfaction Qualitative description by an open question in the phone survey Assessed only once. Phone call will be performed between march 2021 and June 2021
Secondary Description of the characteristics of these patients and of the hypnosis sessions Patients'characteristics described in medical records At inclusion
See also
  Status Clinical Trial Phase
Recruiting NCT04078698 - Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A
Recruiting NCT05670301 - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases N/A
Completed NCT03266172 - A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses Phase 1
Completed NCT03649412 - A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 Phase 1
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Completed NCT00975936 - Phase 0 Microdose Study Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Completed NCT01210716 - Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Phase 3
Completed NCT00820469 - Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab Phase 4
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Withdrawn NCT03239600 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) Phase 2
Completed NCT04872257 - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo N/A
Recruiting NCT06019611 - Epidural Stimulation in Multiple Sclerosis N/A
Recruiting NCT05030779 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus Early Phase 1
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT04005456 - Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design N/A
Recruiting NCT05085444 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma Early Phase 1
Recruiting NCT05853835 - First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641 Phase 1